Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Abstract
Purpose:
Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death.
Materials and Methods:
A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival.
Results:
Of 425 eligible men 211 were randomized to observation and 214 to adjuvant radiation. Of those men under observation 70 ultimately received radiotherapy. Metastasis-free survival was significantly greater with radiotherapy (93 of 214 events on the radiotherapy arm vs 114 of 211 events on observation; HR 0.71; 95% CI 0.54, 0.94; p = 0.016). Survival improved significantly with adjuvant radiation (88 deaths of 214 on the radiotherapy arm vs 110 deaths of 211 on observation; HR 0.72; 95% CI 0.55, 0.96; p = 0.023).
Conclusions:
Adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival.
References
- 1 : Cancer statistics, 2008. CA Cancer J Clin2008; 58: 71. Google Scholar
- 2 : Racial treatment trends in localized/regional prostate carcinoma: 1992–1999. Cancer2005; 103: 538. Google Scholar
- 3 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005; 352: 1977. Google Scholar
- 4 : The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol2004; 171: 1393. Link, Google Scholar
- 5 : Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol2008; 179: 2212. Link, Google Scholar
- 6 : Do margins matter?: The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol2008; 179: S47. Link, Google Scholar
- 7 : Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA2006; 296: 2329. Google Scholar
- 8 : Health related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol2008; 26: 112. Google Scholar
- 9 : Nonparametric estimation with incomplete observations. J Am Stat Assoc1958; 53: 457. Google Scholar
- 10 : The changing face of prostate cancer. J Clin Oncol2005; 23: 8146. Google Scholar
- 11 : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med2004; 351: 1513. Google Scholar
- 12 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med2004; 351: 1502. Google Scholar
- 13 : Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol2001; 166: 2286. Link, Google Scholar
- 14 : Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med2008; 358: 1250. Google Scholar
- 15 : Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol2007; 25: 4178. Google Scholar
- 16 : Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol2003; 170: 1189. Link, Google Scholar
- 17 : Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA2004; 291: 1325. Google Scholar
- 18 : Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007; 25: 2035. Google Scholar
- 19 : Radiation therapy after radical prostatectomy: why patience is a virtue! The case for salvage radiation therapy. Rev Urol2002; 4: 90. Google Scholar
